Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
Insider sellers have been noticeably absent for most of the month of October. Nothing like a good old-fashioned stock market rally to get the sellers out from the shadows.
Published:
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
ThinkstockDoes Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts would think so, following the favorable release of this biotech giant’s...
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. on Monday, October 6, 2014.
Published:
Last Updated:
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep the answers short and...
Published:
SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated stock.
Published:
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
Published:
ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will change...
Published:
ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street has loudly stepped up to the plate and advised investors to buy the top biotech...
Published: